vimarsana.com

Latest Breaking News On - Acuitas investments - Page 5 : vimarsana.com

Nuvation Bio (NYSE:NUVB) Rating Reiterated by Wedbush

Wedbush reiterated their outperform rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a report published on Friday morning, Benzinga reports. Wedbush currently has a $5.00 price objective on the stock. NUVB has been the topic of a number of other reports. Royal Bank of Canada increased their price target on shares of […]

Jump Financial LLC Has $260,000 Stock Holdings in Seneca Foods Co (NASDAQ:SENEA)

Jump Financial LLC decreased its stake in Seneca Foods Co. (NASDAQ:SENEA – Free Report) by 43.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,955 shares of the company’s stock after selling 3,794 shares during the period. Jump Financial LLC owned […]

StockNews com Initiates Coverage on Fuel Tech (NASDAQ:FTEK)

Investment analysts at StockNews.com started coverage on shares of Fuel Tech (NASDAQ:FTEK – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the industrial products company’s stock. Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Fuel Tech in a report […]

Raymond James Weighs in on Ero Copper Corp s Q2 2024 Earnings (NYSE:ERO)

Ero Copper Corp. (NYSE:ERO – Free Report) – Research analysts at Raymond James lifted their Q2 2024 EPS estimates for Ero Copper in a research report issued to clients and investors on Wednesday, May 22nd. Raymond James analyst F. Hamed now forecasts that the company will post earnings per share of $0.26 for the quarter, […]

AngioDynamics (NASDAQ:ANGO) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of AngioDynamics (NASDAQ:ANGO – Free Report) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $14.00 target price on the medical instruments supplier’s stock. HC Wainwright also issued estimates for AngioDynamics’ Q4 2024 earnings at ($0.21) EPS, Q2 2025 earnings […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.